HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Personal Folders Download to citation manager Author home page(s): Andrew C. Chang Permission Requests Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Chang, A. C. Search for Related Content PubMed PubMed Citation Articles by Chang, A. C. Related Collections Lung - other

---

Original Articles: General Thoracic

Invited Commentary

Department of Surgery, University of Michigan Medical Center, TC2120G/5344, 1500 East Medical Center Dr, Ann Arbor, MI 48109

(Email: andrwchg@umich.edu).

The first 20% of the full text of this article appears below.

Radiofrequency ablation (RFA) for the treatment of either primary or metastatic lung cancer has been used as an alternative, particularly for patients who have limited pulmonary reserve or who are otherwise considered to be "medically inoperable." Although this emerging technology is the focus of an ongoing cooperative group pilot trial (American College of Surgeons Oncology Group Z4033) for patients with early stage nonsmall cell lung carcinoma, few studies have validated this technique biologically. Schneider and colleagues [1] present their study of intraoperative RFA with an "ablate and resect" approach for the treatment of pulmonary metastases. The purpose of their study was to . . . [Full Text of this Article]